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ABSTRACT 
Since HDL glycoprofiles are associated with HDL functional capacity we set out to determine 
whether diet can alter the glycoprofiles of key HDL-associated proteins, including ApoE, a potent driver 
of chronic disease risk. Ten healthy subjects consumed a fast food (FF) and a Mediterranean (Med) diet 
for 4 days in randomized order, with a 4-day wash-out between treatments. A multiple reaction 
monitoring (MRM) method was used to characterize the site-specific glycoprofiles of HDL proteins, and 
HDL functional capacity was analyzed. We describe for the first time that ApoE has 7 mucin-type O-
glycosylation sites, which were not affected by short-term diet. The glycoprofiles of other HDL-
associated proteins were also unaffected, except a di-sialylated ApoC-III glycan was enriched after Med 
diet, while a non-sialylated ApoC-III glycan was enriched after FF diet. Twenty-five individual 
glycopeptides were significantly correlated with cholesterol efflux capacity and 21 glycopeptides were 
correlated with immunomodulatory capacity. Results from this study indicate that the glycoprofiles of 
HDL-associated proteins including ApoE are correlated with HDL functional capacity but generally 
unaffected by diet in the short-term, except ApoC-III sialylation. These results suggest that HDL protein 
glycoprofiles are affected by both acute and long-term factors, and may be useful for biomarker 
discovery. 
 
Keywords: Cholesterol Efflux; High-Density Lipoprotein; Glycomics; Glycoproteomics; ApoE; ApoC-III; 
Fast Food Diet; Mediterranean Diet 
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1 INTRODUCTION 
High density lipoprotein (HDL) particles are protein-lipid complexes that transport lipophilic 
molecules in the blood. Primarily known for their function in regulating cellular cholesterol 
concentrations through efflux of cholesterol out of cells and transport of cholesterol to the liver, HDL 
particles also perform a number of additional functions including immunomodulatory, anti-
inflammatory, anti-proteolytic, and other functions.1–3 HDL particles are heterogeneous and undergo 
significant remodeling in vivo.4 As many as 16 distinct HDL subclasses have been described, and based 
on their protein composition likely play distinct biological roles.5 The proteomic composition of HDL 
particles is well known to affect HDL function and is altered in a variety of disease states.6–8 Recently it 
has also been demostrated that HDL-associated proteins are highly glycosylated.9 HDL-associated 
proteins enriched in HDL particles have a different site-specific glycosylation pattern from the same 
proteins found in plasma,10 and their glycosylation may be useful for diagnostic purposes.11 Importantly, 
key HDL proteins are differentially glycosylated in multiple disease states vs. healthy individuals, and 
site-specific glycosylation of HDL-associated proteins is associated with HDL’s immunomodulatory 
capacity.12 
Apolipoprotein E (ApoE) genotype is one of the most important risk factors for a number of age-
associated diseases,13 and the single greatest genetic risk factor for Alzheimer’s Disease.14 ApoE is a 
component of HDL particles that is involved in mediating HDL functional capacity.15,16 Although ApoE is 
known to be a glycosylated protein, ApoE glycosylation has only been partially characterized. To date, no 
comprehensive site-specific glycosylation analysis across all detectable glycosylation sites has been 
obtained for ApoE. 
Dietary changes can modify HDL cholesterol efflux capacity,17 and anti-inflammatory capacity 
(reviewed in18), however, it is not clear whether diet alters HDL glycoprofiles or whether HDL 
glycoprofiles are also associated with HDL’s cholesterol efflux capacity. The half-life of ApoA-I, the main 
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protein constituent of HDL, is approximately 4 days,19and we previously showed that the HDL lipidome is 
drastically remodeled by diet in 4 days.20 Hence, we postulated that if there is an effect of diet on HDL 
glycoprofiles it may be visible within this time frame. 
In this pilot study, we hypothesized that a 4-day dietary intervention period measurably alters 
HDL site-specific glycoprofiles and HDL functionality. Specifically, the effects of consuming a fast food 
(FF) diet vs. a Mediterranean (Med) diet were compared to broadly test the hypothesis that large-scale 
shifts in overall dietary pattern in the short-term can alter HDL glycoprofiles and functionality. The FF 
arm of the study was designed to reflect a typical Western diet, which is enriched in red meat, simple 
sugars, fat, saturated fat, and cholesterol, and low in fresh fruits, vegetables and fiber.21–25 The Med arm 
of the study was designed to reflect what is currently widely thought to be a healthy diet enriched in 
fresh fruits, vegetables, fiber, monounsaturated fat, and polyunsaturated fat, particularly omega-3 fatty 
acids.26–31 HDL function and site-specific glycoprofiles in response to the two dietary patterns were 
assessed and compared. 
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2 MATERIALS AND METHODS 
2.1 Study design and subjects 
Ten healthy human subjects (5 male and 5 female) were recruited into a randomized order, cross-
over study. Each subject was given both FF and Med diet for 4 days in duration in randomized order with 
a 4-day washout between treatments. The study dietary plan was balanced for each participant’s daily 
caloric requirements calculated using the Harris-Benedict equation. The study foods for the Med diet 
were purchased at a local grocery store and prepared for participants to consume at home, while the 
foods for the FF diet were purchased from a local fast food restaurant. An overnight fasted blood draw 
was taken from the antecubital vein by a licensed phlebotomist, and anthropometric measurements 
were taken on the first and the morning after the last day of each study arm. Plasma or serum was 
separated within 1 hour of the blood draw. Samples were aliquoted immediately and stored at -80°C. 
One sample was sent for a lipid panel test to the University of California Davis Medical Center pathology 
lab. 
Study subjects were 18-25 years old, non-smokers, with BMI ranging from 21.2 to 32.9 kg/m2 . 
Subjects were free from any disease diagnoses including anemia, diabetes, thyroid disease, metabolic 
syndrome, cancer, and cardiovascular diseases. Subjects with extreme dietary or exercise patterns, or 
taking medications or supplements that alter lipoproteins were excluded from the study. The study was 
approved by the University of California Davis Institutional Review board and registered at 
clinicaltrials.gov (NCT03205254). 
2.2 Diet 
On the FF arm, depending on the participant’s calculated caloric requirement, 1 or 2 frosted 
strawberry pop-tarts were given for breakfast, and different hamburgers with or without fries were 
assigned to subjects for lunch and dinner, with soda consumed ad libitum. On the Med arm, breakfast 
included high fiber cereal in 1% milk with one small banana. Lunch was a study salad with canned tuna 
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or chicken, while dinner was minestrone soup, multigrain blend, tomato basil marinara, mixed 
vegetables, and extra virgin olive oil (EVOO) adjusted to the calorie level. Almonds and other dried fruits 
and nuts were provided as snacks between meals according to the prescribed calorie level. The snacks 
on the Med diet were provided to meet each individual’s daily calorie requirement and to maintain the 
FF and Med arms isocaloric. The study diet menu for FF and Med at the 2000 kcals/day level is shown in 
Supplemental Table S1. 
2.3 HDL isolation 
A 2-step density based sequential flotation ultracentrifugation method was used to isolate HDL 
particles as previously described.12 Two ml plasma was adjusted using a concentrated potassium 
bromide (KBr) solution (density 1.340 g/mL) to a density of 1.063 g/mL, before being underlaid to KBr 
solution of 1.063 g/mL into an ultracentrifugation tube (OptiSeal, Beckman Coulter). A 2 mL supernatant 
was removed after an ultracentrifugation spin at 110,000 rpm for 3 hours and 10 minutes. The HDL-
containing bottom layer was then adjusted to a density of 1.21 g/mL by adding the same concentrated 
KBr solution, followed by underlaying to KBr solution of 1.21 g/mL in two ultracentrifugation tubes. After 
the second ultracentrifugation spin at 110,000 rpm for 3 hours and 20 minutes, 1 mL supernatant of HDL 
fraction from each ultracentrifugation tube was combined and dialyzed twice using Amicon Ultra-
4,MWCO 10 KDa filter units. The HDL fraction was reconstituted in either LC-MS water for 
glycoproteomics and ELISA assays, or PBS for functional assays. Samples were stored in -80°C until 
analysis. All KBr solutions were freshly prepared and verified using a densitometer (Mettler Toledo, 
Columbus, OH). Ultracentrifugation was performed on a Beckman Optima MAX-TL equipped with a TLA-
110 fixed-angel roter (Beckman Coulter, k factor 13.04) 
2.4 Apolipoprotein E glycoprofile 
The ApoE glycoprofile was identified using purified Apo E standard from human plasma obtained 
from Sigma-Aldrich (St. Louis, Missouri). The proteins were digested and analyzed as previously 
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described.10 In brief, proteins were denatured with dithiothreitol and alkylated with iodoacetamide. The 
denatured proteins were then digested with 2μg of sequencing grade trypsin (Promega, Madison, WI) 
for 18 h at 37°C. The protein tryptic digest was analyzed on a nanoLC Q-Exactive Orbitrap MS platform 
(Thermo Scientific, Waltham, MA) equipped with a 75 μm × 150 mm Magic C18 reversed phase column. 
Peptides and glycopeptides were identified using Byonic software (Protein Metrics, Inc.) set to a 
precursor and fragment mass tolerance of 10 ppm and a false discovery rate of < 1%. Only peptides and 
glycopeptides with a log probability greater than 2 were considered. 
2.5 HDL glycoproteomics 
The following glycoproteins were monitored and both the glycoprotein and the site-specific 
glycosylation quantities were determined for ApoE, apolipoprotein C-III (ApoC-III), alpha-1-antitrypsin 
(A1AT), and alpha-2-HS-glycoprotein (A2HSG, or fetuin A). Serum amyloid A (SAA) 1 and 2, which are the 
inducible and pro-inflammatory isoforms, are not glycosylated, thus only the protein quantity was 
measured. The mixture of peptides and glycopeptides was analyzed using an Agilent 1290 infinity LC 
system coupled with an Agilent 6490 triple quadrupole (QQQ) mass spectrometer (Agilent technology, 
Santa Clara, CA) using a previously published method.10 Briefly, isolated HDL samples and protein 
standards were digested using trypsin and then separated on the Agilent eclipse plus C18 (RRHD 1.8 μm, 
2.1 mm × 100 mm) UHPLC analytical column. Analytes were monitored using dynamic multiple reaction 
monitoring (dMRM) mode. Each glycopeptide transition was composed of the glycopeptide molecular 
ion of a certain charge as precursor and the glycopeptide diagnostic oxonium ions such as m/z 204.08 
(HexNAc), 366.14 (Hex1HexNAc1), 292.09 (Neu5Ac), and 274.09 (Neu5Ac − H2O) as product ions. The 
MRM transitions monitored for ApoC-III, A1AT, and A2HSG were mentioned in the previously published 
report, and the transitions for ApoE were listed in Supplemental Table S2. The dMRM data were 
analyzed using Agilent Mass Hunter quantitative analysis software version B-05−02/build 5.2.365.0. 
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The glycoforms were named in the format of protein, position, N/O glycan, and followed by the 
glycan composition. The glycan composition is a four-digit number where each digit represents the 
number of hexose (Hex) (mannose or galactose), N-acetylhexosamine (HexNAc) (N-
acetylgalactosamine), fucose (Fuc), and N-acetylneuraminic acid or sialic acid (Neu5Ac). For example, 
ApoE_290_O_1101 represents the glycopeptide of ApoE with an O-linked glycan consisting of 1 Hex, 1 
HexNAc, 0 Fuc, and 1 Neu5Ac attached at position 290. The intensities of all glycoforms were normalized 
to the unglycosylated indicator peptide of the corresponding protein. 
2.6 HDL ApoA-I and Cholesterol Efflux Assay 
HDL ApoA-I was measured using the Human Apolipoprotein AI ELISA kit (ab189576) from Abcam 
(Cambridge, MA) in isolated HDL fractions. HDL cellular cholesterol efflux ability was measured via a 
commercially available kit (Abcam, ab196985) according to the manufacturer’s instructions with the 
following modifications. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy blood 
donors via Ficoll gradient extraction. Isolated PBMCs were then cultured in RPMI 1640 without HEPES 
containing 1xPSG and 10% FBS and T- and B-cell populations removed via adhesion properties. 
Remaining adherent PBMCs were differentiated into macrophage with 20 ng/mL of human macrophage 
colony stimulating factor for 72 hours. Fully differentiated macrophage cells were then lipid loaded 
using fluorescently-labeled cholesterol (BODIPY) for 4 hours, washed, and incubated with isolated HDL 
samples and assay controls for an additional 4 hours. The volume of each HDL sample added was 
calculated to deliver 25 μg total protein based on the protein concentration of the isolated HDL fraction 
measured by nanodrop. The final volume in each well was constant. ACAT inhibitor and cAMP, which 
induces cholesterol efflux by the ATP binding cassette A1 (ABCA1), are included in the kit reagent. 
Cellular supernatant was removed and transferred to a new plate and cells were lysed using M-PER cell 
lysis buffer. Concentrations of fluorescently-labeled cholesterol present in the supernatant and the cells 
were then measured separately using a microplate reader (Synergy H1 Hybrid Multi-Mode Reader, 
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BioTek, VT), with the emission and excitation wavelengths of 482 and 515 nm, respectively. The 
percentage cholesterol efflux is calculated as below. 
% Chol Efflux = 
Fluorescence Intensity of Media
Fluorecence Intensity of Cell Lysate + Media
 × 100% 
2.7 HDL Immunomodulatory Assay 
Isolated HDL from each subject was supplemented into the media (RPMI 1640, 10% FBS, 1× PSG) 
of primary PBMCs (4×104 cells/well) at a normalized concentration of 1 mg/mL of protein for 1 hour 
before exposing the HDL-cell mixture to 20 μg/mL of citrullinated fibrinogen immune complexes (cFb-IC) 
as an inflammatory stimulant specific to the Fc-γ receptor pathway.32 Cells were incubated for 18 hours 
to allow time for cytokine secretion after which the supernatants of each reaction were collected and 
TNF-α was measured by ELISA (Peprotech, Rocky Hill, NJ). Additionally, a positive control reaction 
consisting of PBMCs stimulated with cFb-ICs without any added HDL and a negative control consisting of 
unstimulated PBMCs were used to assess the effects of HDL on PBMC cytokine secretion. The % TNF-α 
suppression was calculated as below: 
% TNF-α Suppression = (1 - 
TNFα (ng/mL) in Sample
TNFα (ng/mL) in Positive Control
) ×100% 
2.8 Statistical Analysis 
The total amount of each protein (ApoE, ApoC-III, A1AT, A2HSG, and SAA) was quantified as the 
total intensity for the unglycosylated peptide with the highest response (i.e. indicator peptide) divided 
by the total protein amount in the isolated HDL fraction measured by nanodrop. For the glycoform 
quantitation, the intensity of each glycopeptide was normalized to the intensity of its corresponding 
unglycosylated indicator peptide. 
A differential abundance test was applied to the normalized site-specific glycosylation data using 
a mixed linear model, with the R package, limma.33 Multiple test correction was performed on the p-
values using the Benjamini-Hochberg method whenever more than 10 variables were tested. The same 
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linear model was also applied on HDL cholesterol efflux, TNF-α suppression, and HDL ApoA-I level. Data 
were log2 transformed before linear model analysis and the shapiro.test function in R was used to 
perform the Shapiro-Wilk test of normality. The Pearson’s correlation test was applied to find the 
correlation between different variables. 
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3 RESULTS 
3.1 Baseline Characteristics and Dietary Records 
All anthropometric values, blood pressure, and blood lipid levels were in the expected ranges and 
did not change significantly across the study period (Table 1). The BMIs showed that subjects were 
normal to slightly overweight. Summary data from the three-day diet records from baseline and during 
the two study treatments are listed in Supplemental Table S3. The total calorie intake of each subject 
was relatively equivalent to their baseline level. The daily calorie intake at baseline was not statistically 
significantly different from FF (p = 0.506) or Med (p=0.277). Carbohydrate intake was not significantly 
different between the two treatments. 
 
Table 1: Subject anthropometric and clinical values (mean and standard deviation) before and after FF 
and Med diet. 
variable 
FF Med 
Pre 
Mean (SD) 
Post 
Mean (SD) 
Pre 
Mean (SD) 
Post 
Mean (SD) 
Height (m) 1.71 ( 0.09) 1.71 ( 0.09) 1.71 ( 0.09) 1.71 ( 0.09) 
Weight (kg) 68.90 (12.92) 69.23 (13.18) 69.24 (13.08) 68.51 (12.91) 
BMI (kg/m2) 24.33 ( 3.69) 24.46 ( 3.88) 24.47 ( 3.79) 24.21 ( 3.67) 
Age (yrs) 22.10 ( 2.33) 22.10 ( 2.33) 22.10 ( 2.33) 22.10 ( 2.33) 
Systolic Blood Pressure 122.93 (14.53) 123.57 (17.83) 118.93 ( 9.75) 121.10 (12.58) 
Diastolic Blood Pressure 77.63 (14.30) 76.63 (13.25) 76.37 ( 7.27) 75.63 ( 8.43) 
Waist Circumference (cm) 76.63 ( 9.83) 76.63 ( 9.83) 76.63 ( 9.83) 76.63 ( 9.83) 
Hip Circumference (cm) 99.88 ( 6.97) 99.88 ( 6.97) 99.88 ( 6.97) 99.88 ( 6.97) 
Total Cholesterol (mg/dL) 151.00 (30.92) 154.00 (18.10) 162.20 (16.04) 148.90 (17.93) 
HDL-cholesterol (mg/dL) 51.10 (14.37) 53.89 (13.14) 52.80 (12.43) 50.50 (10.82) 
LDL cholesterol (mg/dL) 87.10 (22.34) 87.67 (11.39) 93.00 (16.13) 86.50 (15.15) 
Triglycerides (mg/dL) 64.40 (24.22) 61.78 (21.78) 82.70 (29.72) 59.60 (20.05) 
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3.2 HDL ApoA-I Content and Functional Measures 
The average HDL ApoA-I concentration measured in this study population was 156.96 (±28.81) 
mg/dL. The change in HDL ApoA-I was statistically significant by mixed linear model analysis (p = 0.015 
(Figure 1-A)). The increase after FF was not statistically significant, but the decrease after Med was (p = 
0.043). Neither the cholesterol efflux capacity (18.85 ± 1.54 and 19.85 ± 1.82 % before and after FF, and 
20.07 ± 3.50 and 20.88 ± 3.34 % before and after Med) nor the capacity to suppress TNF-α by stimulated 
macrophages (0.35 ± 0.13 and 0.37 ± 0.14 % before and after FF, and 0.37 ± 0.19 and 0.33 ± 0.14 % 
before and after Med) were significantly affected by either of the dietary interventions (Figure 1-B&C). 
HDL cholesterol efflux capacity was positively associated with TNF-α suppression (rho = 0.304, p = 0.057, 
Figure 1-D). 
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Figure 1: A-C: Box plots of HDL ApoAI (mg/dL) (A), % HDL cholesterol efflux (A), and % macrophage TNF-
α suppression (B) for subjects before and after FF and Med diets, with unadjusted P-values. Lines with 
the same color represent the same subjects. D: Scatter plot of % HDL cholesterol efflux and % TNF-α 
suppression. E&F: Box plots of HDL glycans ApoC3_74_O_1102 and ApoC3_74_O_2230 before and after 
FF and Med diets, with unadjusted P-values 
 
3.3 HDL Glycopeptides 
Eighty-six glycopeptides were detected across the 4 measured proteins across all samples. ApoE 
was added to the existing MRM site-specific glycosylation method described previously.10 Four 
glycosylation sites (Thr194, Ser197, Ser263, and Ser296) and three putative glycosylation sites 
(Ser129/Thr130, Ser76/Thr83/Thr89, and Thr289/Ser290) were detected. The three putative glycosylation 
sites have multiple possible O-glycan linkage sites (serine and threonine) in the fragmented peptides 
thus it is not possible to determine to which exact amino acid the glycans are attached. Across these 7 
glycosylation sites a total of 25 glycoforms were detected and monitored. The sites and structures are 
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shown in Figure 2. The glycans found on ApoE include simple attachment of a GalNAc residue (e.g. 0100 
on site 194), non-sialylated, non-fucosylated structures (e.g. 2200 on site 197) mono-sialylated 
structures (e.g. 1201 on site 129), disiaylated structures (e.g. 1102 on site 197), and previously 
unidentified fucosylated structures (e.g. 2110 on site 197). ApoE glycopeptides were not affected by 
dietary treatment. 
 
Figure 2: Glycan site-heterogeneity of HDL associated ApoE. Sites of attachment identified include Ser63, 
Ser76/Thr83/Thr89, Ser129/Thr130, Thr194, Ser197, Thr289/Ser290 and Ser296. The 4-digit glycan composition 
number corresponds to the number of hexose (Hex), N-acetylhexosamine (HexNAc) (which could be 
either N-acetylglucosamine (GlcNAc) or N-acetyl-galactosamine (GalNAc)), fucose (Fuc), and N-
acetylneuraminic acid (Neu5Ac) or sialic acid. A glycan containing 1 Hex, 1 HexNAc, 0 Fuc and 2 Neu5Ac 
is designated as 1102. Yellow square: GalNAc; blue square: GlcNAc; yellow circle: Gal; red triangle: Fuc; 
purple diamond: Neu5Ac. *: multiple possible O-glycosylation sites for this glycan. 
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The two most abundant ApoC-III glycans, ApoC3_74_O_1102 and ApoC3_74_O_2230, were 
differentially affected by diet. The disialylated glycopeptide ApoC3_74_O_1102 decreased after FF and 
increased after Med whereas the non-sialylated glycopeptide ApoC3_74_O_2230 increased after FF and 
decreased after Med (unadjusted p = 0.001 and 0.021 respectively, Figure 1-E&F). However, they did not 
remain statistically significant after adjustment for multiple testing (adjusted p = 0.089, adjusted). 
Supplemental Table S4 lists all glycopeptides with their relative abundance before and after FF and 
Med, as well as their linear mixed model p-values. The abundance of the indicator peptides (i.e. the 
quantity) of all measured proteins were also not differentially affected by dietary treatment 
(Supplemental Table S5). 
Although most HDL glycopeptides were not affected differently by diet, many of them were 
correlated with HDL function. Supplemental Figure S1 and S2 are histograms of Pearson’s p-values 
between each glycopeptide and HDL cholesterol efflux and TNF-α suppression capacity. Out of the 86 
measured HDL glycoforms, 25 were significantly correlated with HDL cholesterol eflux, and 21 were 
significantly correlated with TNF-α suppression. Figure 3-A shows the 27 features that were correlated 
with either HDL cholesterol efflux capacity or TNF-α suppression with Spearman’s test. The Spearman’s 
test was used here to reduce the effect of outliers. Glycosylations on A1AT, A2HSG, and ApoE were 
generally positively correlated with HDL cholesterol efflux capacity and macrophage TNF-α suppression, 
while ApoC-III glycans were negatively correlated with HDL cholesterol efflux and TNF-α suppression. 
Figure 3-B-I show 8 site-specific glycans significantly correlated with HDL cholesterol efflux or TNF-α 
suppression after multiple test adjustment (p < 0.05, adjusted). 
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Figure 3: A: Heatmap of Spearman’s rho values between glycoforms and HDL functions. Glycans with p < 
0.05 were selected. B-E: Scatterplot of glycoforms A2HSG_319_O_1102 (B), A1AT_271_N_5402 (C), 
A2HSG_319_O_1101 (D), and ApoE_197_O_2201 (E) correlated with HDL cholesterol efflux capacity. F-I: 
Scatterplot of glycoforms A2HSG_176_N_6501 (F), ApoE_197_O_1100 (G), ApoC3_74_O_1102 (H), and 
A2HSG_346_O_1101 (I) correlated with % TNF-α suppression. 
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4 DISCUSSION 
There is agreement that improving HDL functional capacity is a desirable strategy for preventing 
disease and improving outcomes associated with dyslipidemia. However, it is not at all clear how to 
improve HDL functional capacity. Since diet can modify HDL functional capacity by altering its 
composition, and at the same time, is a major potential source of background variance in free-living 
individuals, we set out to define the impact of diet on HDL composition and function at the timescale of 
4 days. We were interested in the effects of diet on the quantities and glycoprofiles of key HDL-
associated proteins, and whether HDL glycoprofiles are associated with HDL functional capacity. In 
particular, ApoE is of great interest due to the known associations with Alzheimer’s and cardiovascular 
disease risks.34,35 ApoE structure is also known to affect lipoprotein metabolism.36,37 It is not yet clear 
how the glycosylation of ApoE affects its structure and function in the context of HDL particles, though it 
has already been shown that ApoE desialylation reduces binding to HDL and increases binding to VLDL.38 
ApoE does not contain the consensus amino acid sequence (NX(T/S/C)) for N-linked glycosylation, 
and instead is O-glycosylated with mucin-type glycans at Thr194 which is not essential for ApoE 
secretion.39 It was also confirmed that the Thr212 is a glycosylation site by are recent study.40 ApoE 
secreted by macrophages isolated from PBMCs of a single donor with ApoE3/E3 genotype had 8 
different non-, mono-, and di-sialylated glycoforms at site Thr194, and 3 putative new sites were 
identified at Ser290, Thr289 and Ser296.41 In this study we report for the first time an additional 4 O-
glycosylation sites in HDL-associated ApoE, with glycans attached ranging from simple GlcNAc to 
biantennary structures containing both sialic acid and fucose. Future studies are needed to determine 
the exact sites of glycan attachment in the three putative glycosylation sites found in this study. 
The glycoprofile of ApoE was not affected by short-term diet in this study. The glycans attached to 
A1AT and A2HSG were also not changed in response to diet at the time scale tested in this study. Two 
ApoC-III sialylated glycans were changed by diet but did not remain statistically significant after 
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adjustment for multiple testing. In our previous study, the glycan ApoC3_74_O_1102, which decreased 
after FF and increased after Med in this study, was found to be 2-fold higher in HDL compared to 
plasma,10 and was elevated in hemodialysis patients, but decreased in MetS patients compared to 
healthy human controls.12 Although the glycan ApoC3_74_O_2230, which increased after FF and 
decreased after Med in this study, was not detected in our previous study, another non-sialylated ApoC-
III glycan, ApoC3_74_O_0300, was found to be decreased in hemodialysis patients and elevated in MetS 
patients.12 Di-sialylated ApoC-III is enriched in small dense LDL in hemodialysis patients with 
dyslipidemia,42 and was found to be reduced across lipoprotein classes in MetS patients.43 This suggests 
that sialylation of HDL-associated ApoC-III is altered by underlying physiological or disease state as well 
as by short-term dietary changes. 
It has been shown previously that HDL ApoA-I content is associated with cholesterol efflux 
capacity.44 However, although HDL ApoA-I content decreased on the Med diet and increased on the FF 
diet, neither of the two HDL functional capacities tested were significantly altered in response to the 
diets. It is not clear whether the lack of effect of diet on HDL cholesterol efflux capacity, capacity to 
suppress TNF-α secretion in cFb-IC stimulated monocytes, and HDL associated ApoE, A1AT and A2HSG 
content and glycoprofiles is due to the study duration, the sample size, or whether there is truly no 
effect of dietary changes of the type tested in this study on these HDL compositional and functional 
measures. Future studies are needed to determine the longer-term effects of diet, the effects of 
individual dietary components, and the effects of diet in larger cohorts of individuals. 
Despite the lack of effect of short-term diet change, the results from this study suggest that the 
glycoprofiles of HDL-associated proteins are highly correlated with both cholesterol efflux and 
immunomodulatory capacity. The functional role of glycosylation of HDL proteins is not yet known. 
Multiple glycopeptides on A1AT, A2HSG and ApoE were positively correlated, whereas ApoC-III 
glycopeptides were generally negatively correlated with both HDL functional measures. In a previous 
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study we found that HDL that suppressed IL-6 production in LPS-stimulated monocytes were enriched in 
di-sialylated A2HSG, particularly A2HSG_176_N_5402,12 and in this study we similarly found a positive 
correlation between A2HSG_176_N_5402 and both HDL functional measures. We previously found that 
both 5402 and 5412 attached at multiple sites of A1AT were decreased in HDL that suppressed IL-6 
production in LPS-stimulated monocytes,12 whereas in this study we found that glycopeptides containing 
these di-sialylated glycans were positively correlated with cholesterol efflux capacity and the capacity to 
suppress TNF-α secretion in cFb-IC stimulated monocytes. More studies are needed to understand how 
glycosylation affects the structural and functional characteristics of HDL particles, and how glycans alter 
cell-surface interactions between HDL particles and different cell types expressing different cell surface 
HDL receptors. 
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5 CONCLUSION 
In this study we report for the first time that ApoE has 4 additional O-glycosylation sites that were 
not reported previously, and describe an MRM method for profiling ApoE glycosylation. Whereas 
consuming two very different diets for 4 days did not affect the glycoprofile of ApoE, A1AT, or A2HSG 
associated with HDL particles, the quantities of these proteins, or the two HDL functional capacities we 
measured, HDL-associated ApoC-III sialylation and quantity of ApoA-I were altered. Our results suggest 
that overall HDL glycoproteomic composition may be more highly influenced by factors other than diet 
in the short term and thus may be more indicative of longer-term processes and/or disease conditions, 
however, ApoC-III sialylation may be more directly responsive to short-term dietary change. Our results 
also revealed that HDL functionality is strongly associated with HDL glycoproteomic composition, and 
the mechanisms and implications of this association need to be further studied in future studies. 
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Supplemental Table S1: Study diet menu on the FF arm (2000 kcals/day).
Study
Arm
Day Breakfast Snack 1 Lunch Snack 2 Dinner
Day 1 Frosted
StrawberryPop-
tart
Western Ba-
conCheeseburger
Teriyaki BurgerMed order of
fries
Day 2 Frosted
StrawberryPop-
tart
Famous Star
w/Cheese
Super BaconThickburger
Day 3 Frosted
StrawberryPop-
tart
Western Ba-
conCheeseburger
Teriyaki BurgerMed order of
fries
FF
Day 4 Frosted
StrawberryPop-
tart
Famous Star
w/Cheese
Super BaconThickburger
Day 1 1 serving
KashiGoLean
Cereal (180cal) +
50g Grape-Nuts
(180 cal) + 1cup
1\% milk
(102cal) + 1
smallbanana (90
cal)(Total = 552
cal)
1 individual
packetTrek
Mix
(Omega)(170
cal)(Total =
170 cal)
Study Salad 1
(258cal) +
StudyDressing
(133 cal) +1
serving
CannedNo Salt
Tuna
(70cal)(Total:
461 cal)
1 individual
packetTrek
Mix
(SimplyAl-
monds) (210
cal)(Total =
210 cal)
2 servings HeartyMinestrone
Soup(280 cal) + 1serving
MultigrainBlend
withVegetables (180cal) + 1
tablespoonEVOO (119 cal)
+ 1serving TomatoBasil
Marinara (90cal)(Total =
669 cal)
Day 2 1 serving Kashi
GoLeanCereal
(180 cal) +
50gGrape-Nuts
(180 cal) + 1cup
1\% milk (102
cal) + 1small
banana (90
cal)(Total = 552
cal)
1 individual
packet
TrekMix
(Omega)
(170
cal)(Total =
170 cal)
Study Salad 1
(258 cal) +Study
Dressing (133
cal)+ 2 servings
Canned NoSalt
Tuna (140
cal)(Total: 531
cal)
1 individual
packet
TrekMix
(Simply Al-
monds)(210
cal)(Total =
210 cal)
1 serving Whole WheatPasta
(spaghetti, fusilli,or penne)
(210 cal) + 1serving Tomato
BasilMarinara (90 cal) +
1tablespoon EVOO (119cal)
+ 1 serving GrilledChicken
(BalsamicRosemary,
LemonPepper, or Plain –
105cal) + 1 serving
HarvestHodgepodge (30
cal)(Total = 554 cal)
Day 3 1 serving
KashiGoLean
Cereal (180cal) +
50g Grape-Nuts
(180 cal) + 1cup
1\% milk
(102cal) + 1
smallbanana (90
cal)(Total = 552
cal)
1 individual
packetTrek
Mix
(Omega)(170
cal)(Total =
170 cal)
Study Salad 1
(258cal) +
StudyDressing
(133 cal) +1
serving
CannedNo Salt
Tuna
(70cal)(Total:
461 cal)
1 individual
packetTrek
Mix
(SimplyAl-
monds) (210
cal)(Total =
210 cal)
2 servings HeartyMinestrone
Soup(280 cal) + 1serving
MultigrainBlend
withVegetables (180cal) + 1
tablespoonEVOO (119 cal)
+ 1serving TomatoBasil
Marinara (90cal)(Total =
669 cal)
Med
Day 4 1 serving Kashi
GoLeanCereal
(180 cal) +
50gGrape-Nuts
(180 cal) + 1cup
1\% milk (102
cal) + 1small
banana (90
cal)(Total = 552
cal)
1 individual
packet
TrekMix
(Omega)
(170
cal)(Total =
170 cal)
Study Salad 1
(258 cal) +Study
Dressing (133
cal)+ 2 servings
Canned NoSalt
Tuna (140
cal)(Total: 531
cal)
1 individual
packet
TrekMix
(Simply Al-
monds)(210
cal)(Total =
210 cal)
1 serving Whole WheatPasta
(spaghetti, fusilli,or penne)
(210 cal) + 1serving Tomato
BasilMarinara (90 cal) +
1tablespoon EVOO (119cal)
+ 1 serving GrilledChicken
(BalsamicRosemary,
LemonPepper, or Plain –
105cal) + 1 serving
HarvestHodgepodge (30
cal)(Total = 554 cal)
Study Salad 1 = 2 cups romaine (11 cal) +   cup chopped grape tomatoes (16 cal) +   cup quinoa (111)
+   cup chickpeas (73 cal) + 1 tbsp sunflower seeds (47 cal)
Study Salad 2 = 2 cups romaine +   cup chopped grape tomatoes +   cup quinoa +   cup chickpeas + 2
tbsp sunflower seeds (93 cal)
Study Dressing = 1 tbsp olive oil (119 cal) + 1 tbsp balsamic (14 cal)
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Supplemental Table S2: ApoE glycopeptides, precursor, product, retention time, collision energy, and
peptide bearing the glycan.
Glycopeptide PrecursorIon
Product
Ion
Ret Time
(min)
Collision
Energy Peptide
ApoE_76/83/89_O_1320 932.1 204.1 5.0 28.8 S76ELEEQLT83PVAEET89R
ApoE_129/130_O_0300 753.0 204.1 5.0 22.3 GEVQAMLGQS129T130EELR
ApoE_129/130_O_1201 860.7 274.1 5.0 26.2 GEVQAMLGQS129T130EELRVRLASHLR
ApoE_129/130_O_1201 860.7 204.1 5.0 26.2 GEVQAMLGQS129T130EELRVRLASHLR
ApoE_194_O_0100 850.9 204.1 5.9 25.8 AAT194VGSLAGQPLQER
ApoE_197_O_0100 850.9 204.1 5.8 25.8 AATVGS197LAGQPLQER
ApoE_197_O_1100 932.0 204.1 5.0 28.8 AATVGS197LAGQPLQER
ApoE_197_O_1101 1077.5 274.1 5.8 34.0 AATVGS197LAGQPLQER
ApoE_197_O_1101 1077.5 204.1 5.8 34.0 AATVGS197LAGQPLQER
ApoE_197_O_1102 815.7 274.1 6.0 24.6 AATVGS197LAGQPLQER
ApoE_197_O_1102 815.7 204.1 6.0 24.6 AATVGS197LAGQPLQER
ApoE_197_O_1201 786.4 274.1 5.0 23.5 AATVGS197LAGQPLQER
ApoE_197_O_1201 786.4 204.1 5.0 23.5 AATVGS197LAGQPLQER
ApoE_197_O_1300 757.0 204.1 5.0 22.5 AATVGS197LAGQPLQER
ApoE_197_O_1400 824.7 204.1 6.0 24.9 AATVGS197LAGQPLQER
ApoE_197_O_2110 724.4 204.1 5.0 21.3 AATVGS197LAGQPLQER
ApoE_197_O_2200 743.4 204.1 5.0 22.0 AATVGS197LAGQPLQER
ApoE_197_O_2201 840.4 274.1 5.7 25.5 AATVGS197LAGQPLQER
ApoE_197_O_2201 840.4 204.1 5.7 25.5 AATVGS197LAGQPLQER
ApoE_197_O_2202 937.4 274.1 5.7 28.9 AATVGS197LAGQPLQER
ApoE_197_O_2202 937.4 204.1 5.7 28.9 AATVGS197LAGQPLQER
ApoE_197_O_2211 889.1 274.1 5.0 27.2 AATVGS197LAGQPLQER
ApoE_197_O_2211 889.1 204.1 5.0 27.2 AATVGS197LAGQPLQER
ApoE_197_O_2212 986.1 274.1 5.7 30.7 AATVGS197LAGQPLQER
ApoE_197_O_2212 986.1 204.1 5.7 30.7 AATVGS197LAGQPLQER
ApoE_197_O_3210 846.1 204.1 5.0 25.7 AATVGS197LAGQPLQER
ApoE_197_O_3301 962.1 274.1 5.0 29.8 AATVGS197LAGQPLQER
ApoE_197_O_3301 962.1 204.1 5.0 29.8 AATVGS197LAGQPLQER
ApoE_263_O_1210 831.4 204.1 5.0 25.1 LKS263WFEPLVEDMQR
ApoE_263_O_2340 1099.2 204.1 5.0 34.8 LKS263WFEPLVEDMQR
ApoE_263_O_3301 791.9 274.1 5.0 23.7 LKS263WFEPLVEDMQR
ApoE_263_O_3301 791.9 204.1 5.0 23.7 LKS263WFEPLVEDMQR
ApoE_290_O_1100 993.5 204.1 5.0 31.0 VQAAVGT289S290AAPVPSDNH
ApoE_290_O_1101 1139.0 274.1 4.4 36.2 VQAAVGT289S290AAPVPSDNH
ApoE_290_O_1101 1139.0 204.1 4.4 36.2 VQAAVGT289S290AAPVPSDNH
ApoE_296_O_1100 993.5 204.1 4.1 31.0 VQAAVGTSAAPVPS296DNH
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Supplemental Table S3: Macronutrient composition of diet at baseline and after dietary treatment.
Nutrient Variable Baseline
mean ± SD
FF
mean ± SD
Med
mean ± SD
Total Calories (kcal) 2525.57 (951.08) 2686.86 (496.50) 2258.85 (360.68)
Protein (g) 102.41 ( 50.58) 89.93 ( 10.88) 105.18 ( 11.27)
Carbohydrates (g) 304.17 (128.84) 292.32 ( 86.82) 299.00 ( 40.02)
Fat (g) 102.22 ( 59.03) 132.25 ( 21.16) * 85.44 ( 20.01)
Sugar (g) 94.67 ( 36.62) 103.98 ( 68.00) 95.18 ( 16.64)
Fiber (g) 31.40 ( 36.74) 12.90 ( 2.78) ** 57.99 ( 8.55) ***
Saturatexd Fat (g) 33.52 ( 19.01) 44.67 ( 6.69) * 13.24 ( 2.75) ***
Mono-unsaturated Fat (g) 24.07 ( 22.84) 1.89 ( 0.60) *** 41.28 ( 11.74) **
Poly-unsaturated Fat (g) 9.43 ( 6.04) 3.24 ( 1.03) *** 15.63 ( 4.68) **
Trans Fat (g) 0.89 ( 1.07) 2.13 ( 0.44) *** 0.07 ( 0.01) *
Cholesterol (mg) 389.13 (328.15) 229.95 ( 28.63) 94.87 ( 17.53) ***
* Significantly di erent from baseline (p < 0.05)
** Significantly di erent from baseline (p < 0.01)
*** Significantly di erent from baseline (p < 0.001)
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Supplemental Table S4: The relative abundance of glycopeptides before and after treatments, and their
statistical p values.
variable FF_Pre FF_Post Med_Pre Med_Post pvalue padj
A1AT_70_N_5402 0.029 0.03 0.029 0.03 0.96 0.985
A1AT_70_N_5412 0.003 0.003 0.003 0.004 0.614 0.932
A1AT_107_N_5411 0.011 0.007 0.007 0.007 0.353 0.843
A1AT_107_N_5412 0.001 0.001 0.001 0.001 0.196 0.806
A1AT_107_N_6503 0.003 0.004 0.003 0.003 0.922 0.973
A1AT_107_N_6513 0.002 0.002 0.001 0.002 0.776 0.934
A1AT_271_N_5402_MC 0.022 0.014 0.014 0.014 0.405 0.843
A1AT_271_N_5402 0.19 0.204 0.209 0.227 0.956 0.985
A1AT_271_N_5412_MC 8.3e-05 4.7e-05 1.2e-04 6.5e-05 0.493 0.925
A1AT_271_N_5412 0.005 0.005 0.006 0.005 0.681 0.934
A2HSG_156_N_5401 0.007 0.006 0.007 0.007 0.869 0.934
A2HSG_156_N_5402 0.114 0.113 0.116 0.11 0.708 0.934
A2HSG_156_N_5412 0.003 0.002 0.001 8.6e-04 0.258 0.806
A2HSG_156_N_5421 0.052 0.05 0.047 0.049 0.315 0.843
A2HSG_156_N_6502 0.001 4.5e-04 0.002 0.001 0.462 0.889
A2HSG_156_N_6503 0.009 0.01 0.012 0.01 0.421 0.852
A2HSG_156_N_6510 0.037 0.039 0.036 0.039 0.81 0.934
A2HSG_156_N_6513 0.013 0.011 0.012 0.012 0.377 0.843
A2HSG_176_N_5401 0.002 9.2e-04 5.2e-04 0.001 0.019 * 0.417
A2HSG_176_N_5402 0.018 0.019 0.018 0.012 0.992 0.992
A2HSG_176_N_5412 0.003 0.003 0.002 0.002 0.641 0.932
A2HSG_176_N_5431 0.007 0.011 0.009 0.011 0.259 0.806
A2HSG_176_N_6501 0.083 0.089 0.064 0.076 0.618 0.932
A2HSG_176_N_6502 0.005 0.002 0.003 0.004 0.544 0.932
A2HSG_176_N_6503 3.1e-04 6.2e-05 2.8e-04 1.1e-04 NA NA
A2HSG_176_N_6512 0.008 0.008 0.008 0.008 0.759 0.934
A2HSG_176_N_6513 6.9e-04 8.8e-04 7.1e-04 5.0e-04 0.022 * 0.417
A2HSG_176_N_7600 0.015 0.017 0.015 0.016 0.355 0.843
A2HSG_319_O_1101 0.041 0.044 0.047 0.044 0.364 0.843
A2HSG_319_O_1102 0.012 0.012 0.015 0.017 0.248 0.806
A2HSG_319_O_1111 0.0e+00 0.001 3.4e-04 5.4e-04 NA NA
A2HSG_319_O_1201 9.8e-04 0.002 0.002 0.002 0.774 0.934
A2HSG_325_O_1111 4.8e-04 4.4e-04 3.1e-04 2.1e-04 0.988 0.992
A2HSG_346_O_1101 0.484 0.483 0.459 0.478 0.589 0.932
A2HSG_346_O_1102 0.058 0.061 0.061 0.06 0.867 0.934
A2HSG_346_O_2110 8.3e-04 5.8e-04 0.0e+00 1.0e-04 NA NA
A2HSG_346_O_2200 0.002 0.002 0.002 7.9e-04 0.752 0.934
ApoC3_74_O_0300 2.0e-04 1.2e-04 1.3e-04 9.9e-05 0.836 0.934
ApoC3_74_O_0310 0.0e+00 1.5e-04 5.1e-05 5.6e-05 NA NA
ApoC3_74_O_1101 0.04 0.037 0.041 0.036 0.83 0.934
ApoC3_74_O_1101_A_o  0.002 0.003 0.003 0.002 0.228 0.806
ApoC3_74_O_1101_MC 0.015 0.013 0.012 0.012 0.841 0.934
ApoC3_74_O_1102 0.035 0.023 0.024 0.034 0.001 ** 0.089
ApoC3_74_O_1102_A_o  0.025 0.026 0.028 0.024 0.149 0.806
ApoC3_74_O_1102_MC 0.083 0.063 0.07 0.069 0.117 0.806
ApoC3_74_O_1111 8.1e-04 9.5e-04 7.9e-04 6.0e-04 0.076 0.735
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ApoC3_74_O_1202 1.8e-05 3.4e-05 4.1e-04 3.4e-04 NA NA
ApoC3_74_O_1210 0.0e+00 7.5e-05 1.2e-04 7.0e-05 NA NA
ApoC3_74_O_1300 2.3e-04 2.2e-04 8.3e-05 1.5e-04 0.374 0.843
ApoC3_74_O_1311 0.006 0.004 0.003 0.003 0.265 0.806
ApoC3_74_O_2110 6.1e-05 0.0e+00 0.0e+00 0.0e+00 NA NA
ApoC3_74_O_2200 1.0e-05 4.5e-05 9.3e-05 5.3e-05 0.815 0.934
ApoC3_74_O_2211 0.001 0.002 0.002 0.001 0.038 * 0.591
ApoC3_74_O_2212 4.6e-04 6.9e-04 5.7e-04 4.3e-04 0.146 0.806
ApoC3_74_O_2220 0.0e+00 0.0e+00 9.5e-06 0.0e+00 NA NA
ApoC3_74_O_2221 0.027 0.012 0.016 0.011 0.568 0.932
ApoC3_74_O_2230 0.018 0.021 0.018 0.015 0.021 * 0.417
ApoC3_74_O_2230A 0.003 0.003 0.003 0.003 0.062 0.735
ApoC3_74_O_2301 2.6e-05 0.0e+00 1.5e-05 3.6e-05 NA NA
ApoC3_74_O_2302 8.4e-06 1.7e-05 1.9e-05 2.4e-05 0.873 0.934
ApoC3_74_O_2321 6.4e-05 8.4e-05 5.2e-05 5.0e-05 0.628 0.932
ApoE_263_O_1210 0.002 0.002 0.001 0.002 0.272 0.806
ApoE_263_O_2340 4.8e-05 3.0e-05 4.9e-05 2.2e-05 0.853 0.934
ApoE_263_O_3301 0.007 0.004 0.007 0.01 0.185 0.806
ApoE_76/83/89_O_1320 0.002 0.002 0.003 0.003 0.265 0.806
ApoE_129_O_0300 4.5e-04 4.0e-04 2.9e-04 3.2e-04 0.286 0.815
ApoE_129_O_1201 0.008 0.009 0.009 0.008 0.57 0.932
ApoE_194_O_0100 0.009 0.01 0.01 0.01 0.181 0.806
ApoE_197_O_0100 0.009 0.01 0.01 0.01 0.158 0.806
ApoE_197_O_1100 0.002 0.002 0.002 0.002 0.403 0.843
ApoE_197_O_1101 0.033 0.033 0.032 0.031 0.821 0.934
ApoE_197_O_1102 0.085 0.094 0.083 0.089 0.813 0.934
ApoE_197_O_1201 8.1e-05 3.2e-05 3.7e-05 6.1e-05 0.451 0.889
ApoE_197_O_1300 1.9e-04 1.3e-04 1.3e-04 8.9e-05 0.719 0.934
ApoE_197_O_1400 0.001 0.001 0.001 0.001 0.601 0.932
ApoE_197_O_2110 1.5e-04 1.5e-04 8.1e-05 2.3e-04 0.219 0.806
ApoE_197_O_2200 2.3e-04 2.4e-04 1.2e-04 5.4e-04 0.218 0.806
ApoE_197_O_2201 0.006 0.006 0.007 0.007 0.677 0.934
ApoE_197_O_2202 0.025 0.026 0.026 0.026 0.574 0.932
ApoE_197_O_2211 0.001 8.0e-04 0.001 0.002 0.225 0.806
ApoE_197_O_2212 9.7e-04 0.001 0.001 8.4e-04 0.117 0.806
ApoE_197_O_3210 0.004 0.003 0.005 0.004 0.637 0.932
ApoE_197_O_3301 0.002 4.7e-04 6.0e-04 0.002 0.071 0.735
ApoE_289/290_O_1100 0.001 7.6e-04 6.2e-04 5.4e-04 0.396 0.843
ApoE_289/290_O_1101 0.012 0.012 0.012 0.013 0.364 0.843
ApoE_296_O_1100 0.001 0.001 0.001 9.5e-04 0.613 0.932
* P value < 0.05
** P value < 0.01
*** P value < 0.001
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Supplemental Table S5: The relative abundance of HDL proteins before and after treatments, and their
statistical p values, measured by Mass Spectrometry.
Protein FF_Pre FF_Post Med_Pre Med_Post pvalue padj
A1AT 350339.0 376929.3 335635.0 334560.6 0.413 0.918
A2HSG 32267.3 33398.9 34499.4 33358.1 0.674 0.918
ApoC3 732482.3 753695.9 759664.5 888745.1 0.468 0.918
ApoE 167120.3 166877.7 151793.4 162050.5 0.751 0.918
SAA 32203.2 29779.1 30427.8 27479.6 0.815 0.918
* P value < 0.05
** P value < 0.01
*** P value < 0.001
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Supplemental Figure S1 Histogram of Pearson’s p values between HDL glycoforms and HDL cholesterol
e ux capacity
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Supplemental Figure S2 Histogram of Pearson’s p values between HDL glycoforms and HDL % TNF-–
suppression of macrophage cells.
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